Market Trends of Global Gastroparesis Drug Industry
This section covers the major market trends shaping the Gastroparesis Drug Market according to our research experts:
Diabetic Gastroparesis Segment is Expected to Hold a Significant Share in the Gastroparesis Drug Market Over the Forecast Period
Diabetic gastroparesis (DGp) is considered an autonomic neuropathy condition resulting from long-standing poorly controlled type 1 and type 2 diabetes. The diagnostic workup of DGp first excludes obstruction and other causes, including medications that may mimic delayed/disordered gastric emptying. Some symptoms of diabetic gastroparesis are vomiting, nausea, abdominal bloating, abdominal pain, a feeling of fullness after eating just a few bites, vomiting undigested food eaten a few hours earlier, and acid reflux, among others.
According to an article updated by NCBI in March 2022, upper gastrointestinal symptoms are reported in 11% to 18% of patients with diabetes, out of which most of them are associated with delayed gastric emptying or gastroparesis. Gastroparesis is seen in approximately 4.8% of individuals with type 1 diabetes, 1% of those with type 2 diabetes, and 0.1% of those without diabetes. Although there is a stronger association between type 1 diabetes and gastroparesis, the incidence of gastroparesis is much higher in type 2 diabetes patients, and therefore, gastroparesis associated with type 2 diabetes is seen more frequently. Major factors driving the segment's growth are the increasing prevalence of diabetes, increasing awareness about diabetic gastroparesis, and rising product developments by major market players.
The growing diabetes mellitus population worldwide is a major factor leading to the high demand for diabetic gastroparesis drugs. For instance, According to the data published by IDF in September 2021, it is estimated that approximately 537 million adults will be living with diabetes in 2021, and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. It is also estimated that 3 in 4 adults with diabetes will live in low- and middle-income countries in 2021. Furthermore, according to an article published by frontiers in March 2022, a study in India showed that the prevalence of diabetes mellitus in India was 9.3%. Among those with diabetes mellitus, 45.8% were aware, 36.1% were on treatment, and 15.7% had it under control. Hence, with the increasing prevalence of diabetes, diabetic gastroparesis is also expected to increase, thus enhancing segment growth.
Furthermore, developments by key market players are also enhancing segment growth. For instance, in December 2021, Evoke's' commercialization partner EVERSANA conducted a GIMOTI Awareness, Trial, and Usage (ATU) study to observe a continued physician and provider awareness, trial, and utilization of GIMOTI (a drug for diabetic gastroparesis) following market developments in the second half of 2021.
Thus, the increasing prevalence of diabetes and developments by key market players are driving the segment's growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the gastroparesis drug market due to the increasing aging population and the rising number of surgical procedures. The United States dominated the market owing to a large prediabetic population, favorable reimbursement policies, and more awareness about the condition. For instance, according to the data from CDC in June 2022, 96 million people aged 18 years or older have prediabetes (38.0% of the adult United States population). Furthermore, increasing healthcare expenditure, a growing number of hospitals, and the presence of well-established healthcare infrastructure are also responsible for the dominance of the region in the market.
Additionally, according to the data by IDF in September 2021, an estimated 51 million people were living with diabetes in 2021 in North America and the Caribbean region, and this number is projected to rise to 57 million by 2030, and 63 million by 2045. Furthermore, according to the data published by Diabetes Canada in February 2022, it is estimated that the number of people suffering from diabetes including type 1, type 2 diagnosed, and type 2 undiagnosed is 5,719,000 in 2022, and this is expected to rise to 7,277,000 by 2032. Among Canadians, it is estimated that 30% live with diabetes or prediabetes, and only 10% live with diagnosed diabetes. The out-of-pocket cost per year for type 1 diabetes on multiple daily insulin injections is around USD 1,100 to USD 2,600 in 2022.
Furthermore, key developments by major players in the region are expected to boost the market growth. For instance, in July 2022, Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray for diabetic gastroparesis, announced that the Canadian Intellectual Property Office granted the company a key patent for its previously submitted application (CA 2984736). The received patent is for GIMOTI's method of use.
Thus, due to factors such as the increasing prevalence of diabetes and developments by major players, are expected to increase the sales of gastroparesis drugs in North America during the forecast period.
